188 related articles for article (PubMed ID: 22571483)
1. Intracellular disposition of methotrexate in acute lymphoblastic leukemia in children.
de Beaumais TA; Jacqz-Aigrain E
Curr Drug Metab; 2012 Jul; 13(6):822-34. PubMed ID: 22571483
[TBL] [Abstract][Full Text] [Related]
2. Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells.
Panetta JC; Sparreboom A; Pui CH; Relling MV; Evans WE
PLoS Comput Biol; 2010 Dec; 6(12):e1001019. PubMed ID: 21152005
[TBL] [Abstract][Full Text] [Related]
3. A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia.
Panetta JC; Yanishevski Y; Pui CH; Sandlund JT; Rubnitz J; Rivera GK; Ribeiro R; Evans WE; Relling MV
Cancer Chemother Pharmacol; 2002 Nov; 50(5):419-28. PubMed ID: 12439601
[TBL] [Abstract][Full Text] [Related]
4. The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX).
Giverhaug T; Loennechen T; Aarbakke J
Gen Pharmacol; 1999 Oct; 33(4):341-6. PubMed ID: 10523073
[TBL] [Abstract][Full Text] [Related]
5. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis.
Dervieux T; Furst D; Lein DO; Capps R; Smith K; Walsh M; Kremer J
Arthritis Rheum; 2004 Sep; 50(9):2766-74. PubMed ID: 15457444
[TBL] [Abstract][Full Text] [Related]
6. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.
Adam de Beaumais T; Dervieux T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
Cancer Chemother Pharmacol; 2010 Sep; 66(4):653-8. PubMed ID: 20033410
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity.
Panetta JC; Wall A; Pui CH; Relling MV; Evans WE
Clin Cancer Res; 2002 Jul; 8(7):2423-9. PubMed ID: 12114448
[TBL] [Abstract][Full Text] [Related]
8. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.
Masson E; Relling MV; Synold TW; Liu Q; Schuetz JD; Sandlund JT; Pui CH; Evans WE
J Clin Invest; 1996 Jan; 97(1):73-80. PubMed ID: 8550853
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy.
Leclerc GJ; Mou C; Leclerc GM; Mian AM; Barredo JC
Leukemia; 2010 Mar; 24(3):552-62. PubMed ID: 20072153
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of methotrexate resistance in acute leukemia. Decreased transport and polyglutamylation.
Gorlick R; Cole P; Banerjee D; Longo G; Li WW; Hochhauser D; Bertino JR
Adv Exp Med Biol; 1999; 457():543-50. PubMed ID: 10500832
[TBL] [Abstract][Full Text] [Related]
11. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.
Dervieux T; Brenner TL; Hon YY; Zhou Y; Hancock ML; Sandlund JT; Rivera GK; Ribeiro RC; Boyett JM; Pui CH; Relling MV; Evans WE
Blood; 2002 Aug; 100(4):1240-7. PubMed ID: 12149204
[TBL] [Abstract][Full Text] [Related]
12. Effects of overexpression of gamma-Glutamyl hydrolase on methotrexate metabolism and resistance.
Cole PD; Kamen BA; Gorlick R; Banerjee D; Smith AK; Magill E; Bertino JR
Cancer Res; 2001 Jun; 61(11):4599-604. PubMed ID: 11389096
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate.
Ogungbenro K; Aarons L;
J Pharmacokinet Pharmacodyn; 2014 Apr; 41(2):173-85. PubMed ID: 24651962
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug Transporters.
Hu YH; Zhou L; Wang SS; Jing X; Guo HL; Sun F; Zhang Y; Chen F; Xu J; Ji X
Curr Pharm Des; 2019; 25(6):627-634. PubMed ID: 30931851
[TBL] [Abstract][Full Text] [Related]
15. Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate.
Innocenti F; Danesi R; Di Paolo A; Loru B; Favre C; Nardi M; Bocci G; Nardini D; Macchia P; Del Tacca M
Cancer Chemother Pharmacol; 1996; 37(5):409-14. PubMed ID: 8599862
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics of intracellular methotrexate polyglutamates in patients' leukemia cells in vivo.
Lopez-Lopez E; Autry RJ; Smith C; Yang W; Paugh SW; Panetta JC; Crews KR; Bonten EJ; Smart B; Pei D; McCorkle JR; Diouf B; Roberts KG; Shi L; Pounds S; Cheng C; Mullighan CG; Pui CH; Relling MV; Evans WE
J Clin Invest; 2020 Dec; 130(12):6600-6615. PubMed ID: 33164984
[TBL] [Abstract][Full Text] [Related]
17. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine.
Dervieux T; Hancock M; Evans W; Pui CH; Relling MV
Leukemia; 2002 Feb; 16(2):209-12. PubMed ID: 11840287
[TBL] [Abstract][Full Text] [Related]
18. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity.
Galpin AJ; Schuetz JD; Masson E; Yanishevski Y; Synold TW; Barredo JC; Pui CH; Relling MV; Evans WE
Mol Pharmacol; 1997 Jul; 52(1):155-63. PubMed ID: 9224825
[TBL] [Abstract][Full Text] [Related]
19. Plasma Distribution of Methotrexate and Its Polyglutamates in Pediatric Acute Lymphoblastic Leukemia: Preliminary Insights.
Rajšić I; Lazarević S; Đanić M; Al-Salami H; Mooranian A; Vukmirović S; Mikov M; Goločorbin-Kon S
Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):127-134. PubMed ID: 34637107
[TBL] [Abstract][Full Text] [Related]
20. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukaemia cells.
Takemura Y; Kobayashi H; Gibson W; Kimbell R; Miyachi H; Jackman AL
Int J Cancer; 1996 Mar; 66(1):29-36. PubMed ID: 8608962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
